文献速递生殖医学

父母双方对早期胚胎发育的贡献:接受体外受精治疗的夫妇中尿邻苯二甲酸酯及替代物暴露的影响

Parental contributions to early embryo development: influences of urinary phthalate and phthalate alternatives among couples undergoing IVF treatment.
PubMed 文献 · Hum Reprod · 2016-12-07

这项前瞻性队列纳入50对在马萨诸塞州西部接受体外受精的亚 fertile 夫妇,检测双方取卵日尿中17种邻苯二甲酸酯代谢物浓度,分析其与卵裂期和囊胚期胚胎质量的关系。结果显示男性(而非女性)部分代谢物浓度与优质囊胚几率降低相关,男性MEP与优质卵裂期胚胎几率升高相关。

要点

  • 男性尿中邻苯二甲酸单苄酯、单-3-羟基丁基邻苯二甲酸酯、邻苯二甲酸单正丁酯和邻苯二甲酸单甲酯浓度与优质囊胚几率呈负相关。
  • 男性尿中邻苯二甲酸单乙酯浓度与优质卵裂期胚胎几率呈正相关(OR=1.20,95%CI 1.01-1.43,P=0.04)。
  • 女性部分代谢物与囊胚质量呈正相关,但关联在不同囊胚质量指标及配偶水平模型间不一致。

核心结论

  • 男性(而非女性)孕前尿中部分邻苯二甲酸酯及替代物代谢物浓度与优质囊胚质量降低相关,可能发生在基因组激活之后。
  • 作者认为若其他研究证实,这些发现对一般人群和接受体外受精者具有公共卫生和临床意义。

研究设计与样本

  • 前瞻性队列研究,纳入50对在马萨诸塞州西部接受体外受精的亚 fertile 夫妇,来自Baystate Medical Center生育中心SEEDS研究的前50对招募夫妇。
  • 双方在取精和取卵同日采集单次尿样,用液相色谱质谱法量化17种尿液代谢物浓度,并通过比重归一化。
  • 采用广义估计方程估计比值比(OR)和95%CI,尿液邻苯二甲酸酯及替代物作为连续变量,胚胎质量作为二分类变量。

主要发现

  • 50对夫妇共贡献761个卵母细胞,其中423个进展至卵裂期,261个为优质卵裂期胚胎,137个为可移植质量囊胚,47个为优质囊胚。
  • 卵裂期:男性尿邻苯二甲酸单乙酯浓度与优质卵裂期胚胎呈正相关(OR=1.20,95%CI 1.01-1.43,P=0.04),该阶段未观察到其他显著关联。
  • 囊胚期:男性尿邻苯二甲酸单苄酯(OR=0.55,95%CI 0.36-0.84,P=0.01)、单-3-羟基丁基邻苯二甲酸酯(OR=0.37,95%CI 0.18-0.76,P=0.01)、邻苯二甲酸单正丁酯(OR=0.55,95%CI 0.42-0.73,P<0.01)和邻苯二甲酸单甲酯(OR=0.39,95%CI 0.26-0.60,P<0.01)浓度与优质囊胚呈负相关。
  • 男性邻苯二甲酸单(2-乙基己基)酯(OR=0.52,95%CI 0.27-1.00,P=0.05)和环己烷-1,2-二甲酸单羧基异辛酯(OR=0.21,95%CI 0.04-1.03,P=0.05)浓度与优质囊胚呈边缘统计学显著负相关。
  • 男性尿代谢物浓度与可移植质量囊胚几率之间观察到类似的负相关;女性部分代谢物与优质或可移植囊胚质量几率呈正相关,但关联不一致。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 样本量有限,仅纳入50对夫妇,每对夫妇贡献一个周期。
  • 鉴于单次尿样采集和邻苯二甲酸酯半衰期短,暴露的非差异性错分仍是顾虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are preconception urinary concentrations of phthalates and phthalate alternatives associated with diminished early stage embryo quality in couples undergoing IVF? SUMMARY ANSWER: Male, but not female, urinary concentrations of select metabolites of phthalates and phthalate alternatives are associated with diminished blastocyst quality. WHAT IS KNOWN ALREADY: Although phthalates are endocrine disrupting compounds associated with adverse reproductive health, they are in widespread use across the world. Male and female preconception exposures to select phthalates have been previously associated with adverse reproductive outcomes in both the general population and in those undergoing IVF. STUDY DESIGN, SIZE, DURATION: This prospective cohort included 50 subfertile couples undergoing IVF in western Massachusetts. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study includes the first 50 couples recruited from the Baystate Medical Center's Fertility Center in Springfield, MA, as part of the Sperm Environmental Epigenetics and Development Study (SEEDS). Relevant data from both partners, including embryo quality at the cleavage (Day 3) and blastocyst (Day 5) stages, were collected by clinic personnel during the normal course of an IVF cycle. A spot urine sample was collected from both male and female partners on the same day as semen sample procurement and oocyte retrieval. Concentrations of 17 urinary metabolite were quantified by liquid chromatography mass spectrometry and normalized via specific gravity. Generalized estimating equations were used to estimate odds ratios (OR) and 95% CI, with urinary phthalates and phthalate alternatives fitted as continuous variables and embryo quality as a binary variable. MAIN RESULTS AND THE ROLE OF CHANCE: The 50 couples contributed 761 oocytes, of which 423 progressed to the cleavage stage, 261 were high-quality cleavage stage embryos, 137 were transferrable quality blastocysts and 47 were high-quality blastocysts. At the cleavage stage, male urinary monoethyl phthalate concentrations were positively associated with high-quality cleavage stage embryos (OR = 1.20, 95% CI 1.01-1.43, P = 0.04); no other significant associations were observed at this stage. At the blastocyst stage, male urinary concentrations of monobenzyl phthalate (OR = 0.55, 95% CI 0.36-0.84, P = 0.01), mono-3-hydroxybutyl phthalate (OR = 0.37, 95% CI 0.18-0.76, P = 0.01), mono-n-butyl phthalate (OR = 0.55, 95% CI 0.42-0.73, P < 0.01) and monomethyl phthalate (OR = 0.39, 95% CI 0.26-0.60, P < 0.01) were inversely associated with high-quality blastocysts. A borderline statistically significant relationship was observed for male concentrations of mono(2-ethylhexyl) phthalate (OR = 0.52, 95% CI 0.27-1.00, P = 0.05) and cyclohexane-1,2-dicarboxylic acid-monocarboxy isooctyl ester (OR = 0.21, 95% CI 0.04-1.03, P = 0.05) at the blastocyst stage. Similar inverse associations were observed between male urinary phthalate metabolite concentrations and likelihood of transferrable quality blastocysts. For female partners, select metabolites were positively associated with odds of high or transferrable blastocyst quality, but the observed associations were not consistent across blastocyst quality measures or between sex-specific and couples-level models. All models were adjusted for age of both partners, urinary metabolite concentrations of female partners and male infertility status, while models of blastocysts were additionally adjusted for embryo quality at cleavage stage. LIMITATIONS, REASONS FOR CAUTION: Our modest sample included only 50 couples contributing one cycle each. In addition, non-differential misclassification of exposure remains a concern given the single-spot urine collection and the short half-life of phthalates. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest an inverse association between male preconception concentrations of select phthalate metabolites and blastocyst quality, likely occurring after genomic activation. If corroborated with other studies, such findings will have public health and clinical significance for both the general population and those undergoing IVF. STUDY FUNDING/COMPETING INTERESTS: This work was generously supported by grant K22-ES023085 from the National Institute of Environmental Health Sciences. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wu H, Ashcraft L, Whitcomb BW, et al. Parental contributions to early embryo development: influences of urinary phthalate and phthalate alternatives among couples undergoing IVF treatment. Hum Reprod. 2016. PMID: 27927842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。